A phase I trial assessing the IDO1 inhibitor navoximod with the PD-L1 inhibitor atezolizumab showed antitumor activity in various tumor types, including NSCLC; however, no clear benefit of adding navoximod was seen [25]. Here, CD274 is linked to non-small cell lung carcinoma.